-
Switch 2 sales boost Nintendo results but chip shortage looms
-
From rations to G20's doorstep: Poland savours economic 'miracle'
-
Russia resumes strikes on freezing Ukrainian capital
-
'Way too far': Latino Trump voters shocked by Minneapolis crackdown
-
England and Brook seek redemption at T20 World Cup
-
Coach Gambhir under pressure as India aim for back-to-back T20 triumphs
-
'Helmets off': NFL stars open up as Super Bowl circus begins
-
Japan coach Jones says 'fair' World Cup schedule helps small teams
-
Do not write Ireland off as a rugby force, says ex-prop Ross
-
Winter Olympics 2026: AFP guide to Alpine Skiing races
-
Winter Olympics to showcase Italian venues and global tensions
-
Buoyant England eager to end Franco-Irish grip on Six Nations
-
China to ban hidden car door handles in industry shift
-
Sengun leads Rockets past Pacers, Ball leads Hornets fightback
-
Waymo raises $16 bn to fuel global robotaxi expansion
-
Netflix to livestream BTS comeback concert in K-pop mega event
-
Rural India powers global AI models
-
Equities, metals, oil rebound after Asia-wide rout
-
Bencic, Svitolina make history as mothers inside tennis top 10
-
Italy's spread-out Olympics face transport challenge
-
Son of Norway crown princess stands trial for multiple rapes
-
Side hustle: Part-time refs take charge of Super Bowl
-
Paying for a selfie: Rome starts charging for Trevi Fountain
-
Faced with Trump, Pope Leo opts for indirect diplomacy
-
NFL chief expects Bad Bunny to unite Super Bowl audience
-
Australia's Hazlewood to miss start of T20 World Cup
-
Bill, Hillary Clinton to testify in US House Epstein probe
-
Cuba confirms 'communications' with US, but says no negotiations yet
-
From 'watch his ass' to White House talks for Trump and Petro
-
Trump says not 'ripping' down Kennedy Center -- much
-
Sunderland rout 'childish' Burnley
-
Musk merges xAI into SpaceX in bid to build space data centers
-
Former France striker Benzema switches Saudi clubs
-
Sunderland rout hapless Burnley
-
Costa Rican president-elect looks to Bukele for help against crime
-
Hosts Australia to open Rugby World Cup against Hong Kong
-
New York records 13 cold-related deaths since late January
-
In post-Maduro Venezuela, pro- and anti-government workers march for better pay
-
Romero slams 'disgraceful' Spurs squad depth
-
Trump says India, US strike trade deal
-
Cuban tourism in crisis; visitors repelled by fuel, power shortages
-
Liverpool set for Jacquet deal, Palace sign Strand Larsen on deadline day
-
FIFA president Infantino defends giving peace prize to Trump
-
Trump cuts India tariffs, says Modi will stop buying Russian oil
-
Borthwick backs Itoje to get 'big roar' off the bench against Wales
-
Twenty-one friends from Belgian village win €123mn jackpot
-
Mateta move to Milan scuppered by medical concerns: source
-
Late-January US snowstorm wasn't historically exceptional: NOAA
-
Punctuality at Germany's crisis-hit railway slumps
-
Halt to MSF work will be 'catastrophic' for people of Gaza: MSF chief
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC